Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.20. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same period in the prior year, the firm posted ($1.09) earnings per share.
View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

7 equities research analysts have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $68.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $89.14 in the next twelve months. This suggests a possible upside of 81.8% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:

• Dr. Jay R. Luly, Pres, CEO & Director (Age 66, Pay $1.23M)
• Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 67, Pay $652.39k)
• Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 70, Pay $729.75k)
• Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 44, Pay $496.85k)
• Mr. Brendan Luu, Sr. VP of Bus. Devel.
• Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. Communications
• Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 68)
• Dr. Nathalie Adda M.D., Consultant (Age 56) (LinkedIn Profile)

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Enanta Pharmaceuticals' key competitors?

Some companies that are related to Enanta Pharmaceuticals include Bausch Health Companies (BHC), Cerevel Therapeutics (CERE), Galapagos (GLPG), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), CureVac (CVAC), Karuna Therapeutics (KRTX), Prestige Consumer Healthcare (PBH), Pacira BioSciences (PCRX), ACADIA Pharmaceuticals (ACAD) and Indivior (INVVY).
View all of ENTA's competitors.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.13%), Vanguard Group Inc. (7.67%), Farallon Capital Management LLC (7.48%), State Street Corp (6.32%), RA Capital Management L.P. (4.66%) and Northern Trust Corp (4.48%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Granahan Investment Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Acadian Asset Management LLC, Candriam Luxembourg S.C.A., Vanguard Group Inc., and Citigroup Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, Jay R Luly, and Nathalie Adda.
View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Deep Track Capital LP, State Street Corp, Fairmount Funds Management LLC, Invesco Ltd., BlackRock Inc., Walleye Capital LLC, and SG Americas Securities LLC.
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $49.03.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $1.02 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 155 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.